Home/Pipeline/PKM-011

PKM-011

Osteoarthritis

Pre-clinicalActive

Key Facts

Indication

Osteoarthritis

Phase

Pre-clinical

Status

Active

Company

PK MED

About PK MED

PK MED is a privately held, venture-backed French biotech developing a proprietary platform of tailor-designed, injectable, biodegradable micro-implants for localized drug delivery and cell homing. Its lead program, PKM-01 for gout flare, has received FDA clearance to initiate clinical development directly with a Phase 2 study via a 505(b)(2) pathway. The company's strategy leverages known drugs in novel delivery systems to create faster-acting, safer therapies with potentially abbreviated development timelines in areas with significant patient need and limited treatment options.

View full company profile

Therapeutic Areas

Rheumatology Hematology Musculoskeletal Disorders

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
MSC‑OA	Advancells	Phase 1	Active
Osteoarthritis program	Risen Pharma Tech	Clinical (China & US)	Active
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
BRM521	BRIM Biotechnology	Preclinical	Active